Mercer Global Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.29M | Sell |
33,731
-4,869
| -13% | -$931K | 0.01% | 702 |
|
|
2026
Q1 | $7.08M | Sell |
38,600
-3,875
| -9% | -$714K | 0.01% | 625 |
|
|
2025
Q4 | $7.45M | Buy |
42,475
+1,940
| +5% | +$317K | 0.01% | 580 |
|
|
2025
Q3 | $5.68M | Buy |
40,535
+2,920
| +8% | +$395K | 0.01% | 620 |
|
|
2025
Q2 | $4.73M | Buy |
37,615
+28,690
| +321% | +$3.57M | 0.01% | 583 |
|
|
2025
Q1 | $1.22M | Buy |
8,925
+2,450
| +38% | +$350K | ﹤0.01% | 1039 |
|
|
2024
Q4 | $990K | Buy |
6,475
+779
| +14% | +$131K | ﹤0.01% | 1124 |
|
|
2024
Q3 | $1.09M | Sell |
5,696
-630
| -10% | -$132K | ﹤0.01% | 991 |
|
|
2024
Q2 | $1.43M | Sell |
6,326
-1,825
| -22% | -$397K | ﹤0.01% | 819 |
|
|
2024
Q1 | $1.76M | Buy |
8,151
+449
| +6% | +$105K | 0.01% | 758 |
|
|
2023
Q4 | $1.99M | Sell |
7,702
-2,735
| -26% | -$672K | 0.01% | 744 |
|
|
2023
Q3 | $2.68M | Sell |
10,437
-8,835
| -46% | -$2.36M | 0.01% | 609 |
|
|
2023
Q2 | $5.49M | Sell |
19,272
-12,048
| -38% | -$3.59M | 0.02% | 431 |
|
|
2023
Q1 | $8.71M | Buy |
31,320
+16,763
| +115% | +$4.64M | 0.04% | 297 |
|
|
2022
Q4 | $4.03M | Buy |
14,557
+11,310
| +348% | +$3.19M | 0.02% | 485 |
|
|
2022
Q3 | $867K | Sell |
3,247
-139
| -4% | -$29.5K | 0.01% | 900 |
|
|
2022
Q2 | $691K | Sell |
3,386
-248
| -7% | -$50.7K | ﹤0.01% | 996 |
|
|
2022
Q1 | $765K | Sell |
3,634
-648
| -15% | -$141K | ﹤0.01% | 1013 |
|
|
2021
Q4 | $1.03M | Buy |
4,282
+410
| +11% | +$105K | 0.01% | 874 |
|
|
2021
Q3 | $1.1M | Buy |
3,872
+401
| +12% | +$131K | 0.01% | 820 |
|
|
2021
Q2 | $1.2M | Buy |
3,471
+120
| +4% | +$36.4K | 0.01% | 755 |
|
|
2021
Q1 | $937K | Sell |
3,351
-1,340
| -29% | -$361K | 0.01% | 810 |
|
|
2020
Q4 | $1.15M | Sell |
4,691
-16,723
| -78% | -$4.31M | 0.01% | 565 |
|
|
2020
Q3 | $6.08M | Buy |
21,414
+668
| +3% | +$186K | 0.09% | 170 |
|
|
2020
Q2 | $5.55M | Buy |
20,746
+4,451
| +27% | +$1.34M | 0.1% | 152 |
|
|
2020
Q1 | $5.16M | Buy |
16,295
+13,242
| +434% | +$4.02M | 0.11% | 157 |
|
|
2019
Q4 | $906K | Sell |
3,053
-430
| -12% | -$119K | 0.02% | 550 |
|
|
2019
Q3 | $810K | Buy |
3,483
+98
| +3% | +$22.8K | 0.02% | 543 |
|
|
2019
Q2 | $792K | Sell |
3,385
-192
| -5% | -$44.3K | 0.02% | 522 |
|
|
2019
Q1 | $846K | Buy |
+3,577
| New | +$1.13M | 0.03% | 465 |
|
Other funds holding BIIB
Mercer Global Advisors's BIIB Position: Q2 2026 in Review
Mercer Global Advisors reduced its Biogen (BIIB) stake by 13% in Q2 2026, selling an estimated $931K and leaving 33,731 shares worth $7.29M. The position accounts for 0.01% of the portfolio, ranked #702.
Mercer Global Advisors first reported a position in BIIB in Q1 2019 and has held it in 30 quarters since. The position peaked at $8.71M in Q1 2023. 1,044 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Mercer Global Advisors held 33,731 shares of Biogen worth $7.29M as of Q2 2026.
- Mercer Global Advisors sold 4,869 Biogen shares in Q2 2026, an estimated $931K.
- Biogen made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #702 holding.
- Mercer Global Advisors first reported a position in Biogen in Q1 2019 and has held it in 30 quarters since.
- Mercer Global Advisors's Biogen position peaked at $8.71M in Q1 2023.
- 1,044 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.